Welcome to LookChem.com Sign In|Join Free

CAS

  • or

2565-56-2

Post Buying Request

2565-56-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

2565-56-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 2565-56-2 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,5,6 and 5 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 2565-56:
(6*2)+(5*5)+(4*6)+(3*5)+(2*5)+(1*6)=92
92 % 10 = 2
So 2565-56-2 is a valid CAS Registry Number.

2565-56-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-aminoethyl(trimethyl)azanium,bromide,hydrobromide

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:2565-56-2 SDS

2565-56-2Downstream Products

2565-56-2Relevant articles and documents

Oleanolic acid and δ - oleanolic acid derivative and medical application thereof (by machine translation)

-

Paragraph 0092-0094; 0097, (2021/01/15)

The invention discloses a derivative of a pentacyclic triterpene novel AMPK agonist oleanolic acid and δ - oleanolic acid and a medical application thereof, in particular to a compound shown in formula I or formula II. A pharmaceutically acceptable salt or ester or solvate thereof, which can be used to prepare AMPK agonists with enhanced AMPK phosphorylation level activity and to the preparation of drugs for preventing or treating AMPK mediated diseases. The novel pentacyclic triterpene compound has remarkable AMPK agonist activity, and the activity is remarkably superior to the recognized AMPK agonist AICICAR, and meanwhile, the novel pentacyclic triterpene compound has pharmacokinetic properties such as better oral bioavailability and very good safety. (by machine translation)

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 2565-56-2